UK markets close in 38 minutes
  • FTSE 100

    7,095.58
    -14.37 (-0.20%)
     
  • FTSE 250

    22,697.62
    -58.71 (-0.26%)
     
  • AIM

    1,190.50
    -0.01 (-0.00%)
     
  • GBP/EUR

    1.1774
    -0.0009 (-0.08%)
     
  • GBP/USD

    1.3296
    -0.0016 (-0.12%)
     
  • BTC-GBP

    43,799.87
    +735.42 (+1.71%)
     
  • CMC Crypto 200

    1,486.54
    +43.77 (+3.03%)
     
  • S&P 500

    4,614.71
    -40.56 (-0.87%)
     
  • DOW

    34,809.56
    -326.38 (-0.93%)
     
  • CRUDE OIL

    68.02
    -1.93 (-2.76%)
     
  • GOLD FUTURES

    1,795.60
    +10.40 (+0.58%)
     
  • NIKKEI 225

    27,821.76
    -462.16 (-1.63%)
     
  • HANG SENG

    23,475.26
    -376.98 (-1.58%)
     
  • DAX

    15,234.69
    -46.17 (-0.30%)
     
  • CAC 40

    6,762.42
    -13.83 (-0.20%)
     

What Is The Ownership Structure Like For Xenon Pharmaceuticals Inc. (NASDAQ:XENE)?

  • Oops!
    Something went wrong.
    Please try again later.
·4-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Every investor in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. We also tend to see lower insider ownership in companies that were previously publicly owned.

Xenon Pharmaceuticals isn't enormous, but it's not particularly small either. It has a market capitalization of US$1.6b, which means it would generally expect to see some institutions on the share registry. In the chart below, we can see that institutions are noticeable on the share registry. Let's take a closer look to see what the different types of shareholders can tell us about Xenon Pharmaceuticals.

Check out our latest analysis for Xenon Pharmaceuticals

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Xenon Pharmaceuticals?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors have a fair amount of stake in Xenon Pharmaceuticals. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Xenon Pharmaceuticals' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. Our data indicates that hedge funds own 7.0% of Xenon Pharmaceuticals. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Avoro Capital Advisors LLC is currently the company's largest shareholder with 7.0% of shares outstanding. With 5.9% and 3.9% of the shares outstanding respectively, FMR LLC and Capital Research and Management Company are the second and third largest shareholders.

After doing some more digging, we found that the top 20 have the combined ownership of 51% in the company, suggesting that no single shareholder has significant control over the company.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of Xenon Pharmaceuticals

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

I can report that insiders do own shares in Xenon Pharmaceuticals Inc.. It is a pretty big company, so it is generally a positive to see some potentially meaningful alignment. In this case, they own around US$24m worth of shares (at current prices). Most would say this shows alignment of interests between shareholders and the board. Still, it might be worth checking if those insiders have been selling.

General Public Ownership

The general public, with a 32% stake in the company, will not easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Xenon Pharmaceuticals better, we need to consider many other factors. For instance, we've identified 3 warning signs for Xenon Pharmaceuticals that you should be aware of.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting